Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma

Immunotherapy “Shock” with vitiligo due to nivolumab administration as third line therapy in lung adenocarcinoma

Non-small cell lung cancer is still diagnosed at late stage due to the lack of early symptoms and methods of diagnostic prevention. In the past ten years several targeted therapies have been introduced or explored. Tyrosine kinase inhibitors and immunotherapy are currently considered the most effect...

Full description

Bibliographic Details
Main Authors: Paul Zarogoulidis, Haidong Huang, Theodora Tsiouda, Chrysa Sardeli, Georgia Trakada, Lemonia Veletza, Anastasios Kallianos, Christoforos Kosmidis, Aggeliki Rapti, Liana Papaemmanouil, Dimitrios Hatzibougias, Dimitrios Drougas, Chong Bai, Wolfgang Hohenforst-Schmidt
Format: Article
Language:English
Published: Elsevier 2017-01-01
Series:Respiratory Medicine Case Reports
Subjects:
NSCLC
Nivolumab
EBUS
Adenocarcinoma
Online Access:http://www.sciencedirect.com/science/article/pii/S221300711730312X

Internet

http://www.sciencedirect.com/science/article/pii/S221300711730312X

Similar Items